These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

451 related items for PubMed ID: 20637767

  • 1. The Eurocine L3 adjuvants with subunit influenza antigens induce protective immunity in mice after intranasal vaccination.
    Petersson P, Hedenskog M, Alves D, Brytting M, Schröder U, Linde A, Lundkvist A.
    Vaccine; 2010 Sep 07; 28(39):6491-7. PubMed ID: 20637767
    [Abstract] [Full Text] [Related]

  • 2. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A, Haijema BJ, Voorn P, Meijerhof T, van Roosmalen ML, Leenhouts K.
    Vaccine; 2012 Jul 06; 30(32):4884-91. PubMed ID: 22537989
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
    Joseph A, Itskovitz-Cooper N, Samira S, Flasterstein O, Eliyahu H, Simberg D, Goldwaser I, Barenholz Y, Kedar E.
    Vaccine; 2006 May 01; 24(18):3990-4006. PubMed ID: 16516356
    [Abstract] [Full Text] [Related]

  • 5. Influenza antigen-sparing by immune stimulation with Gram-positive enhancer matrix (GEM) particles.
    Saluja V, Visser MR, Ter Veer W, van Roosmalen ML, Leenhouts K, Hinrichs WL, Huckriede A, Frijlink HW.
    Vaccine; 2010 Nov 23; 28(50):7963-9. PubMed ID: 20946860
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant.
    Sui Z, Chen Q, Fang F, Zheng M, Chen Z.
    Vaccine; 2010 Nov 10; 28(48):7690-8. PubMed ID: 20870054
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice.
    Isaka M, Zhao Y, Nobusawa E, Nakajima S, Nakajima K, Yasuda Y, Matsui H, Hasegawa T, Maeyama J, Morokuma K, Ohkuma K, Tochikubo K.
    Microbiol Immunol; 2008 Feb 10; 52(2):55-63. PubMed ID: 18380802
    [Abstract] [Full Text] [Related]

  • 11. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
    Hong SH, Byun YH, Nguyen CT, Kim SY, Seong BL, Park S, Woo GJ, Yoon Y, Koh JT, Fujihashi K, Rhee JH, Lee SE.
    Vaccine; 2012 Jan 05; 30(2):466-74. PubMed ID: 22051136
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant.
    Hasegawa H, Ichinohe T, Strong P, Watanabe I, Ito S, Tamura S, Takahashi H, Sawa H, Chiba J, Kurata T, Sata T.
    J Med Virol; 2005 Jan 05; 75(1):130-6. PubMed ID: 15543590
    [Abstract] [Full Text] [Related]

  • 14. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant.
    Sui Z, Chen Q, Wu R, Zhang H, Zheng M, Wang H, Chen Z.
    Arch Virol; 2010 Apr 05; 155(4):535-44. PubMed ID: 20195654
    [Abstract] [Full Text] [Related]

  • 15. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
    Gupta NK, Tomar P, Sharma V, Dixit VK.
    Vaccine; 2011 Nov 08; 29(48):9026-37. PubMed ID: 21939718
    [Abstract] [Full Text] [Related]

  • 16. Mannan adjuvants intranasally administered inactivated influenza virus in mice rendering low doses inductive of strong serum IgG and IgA in the lung.
    Proudfoot O, Esparon S, Tang CK, Laurie K, Barr I, Pietersz G.
    BMC Infect Dis; 2015 Feb 26; 15():101. PubMed ID: 25887952
    [Abstract] [Full Text] [Related]

  • 17. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA.
    Pediatrics; 2006 Sep 26; 118(3):e570-8. PubMed ID: 16950948
    [Abstract] [Full Text] [Related]

  • 18. Vaccine-specific antibody secreting cells are a robust early marker of LAIV-induced B-cell response in ferrets.
    Cherukuri A, Servat E, Woo J.
    Vaccine; 2012 Jan 05; 30(2):237-46. PubMed ID: 22080173
    [Abstract] [Full Text] [Related]

  • 19. Adjuvanted inactivated influenza A(H3N2) vaccines induce stronger immunogenicity in mice and confer higher protection in ferrets than unadjuvanted inactivated vaccines.
    Ann J, Samant M, Rheaume C, Dumas C, Beaulieu E, Morasse A, Mallett C, Hamelin ME, Papadopoulou B, Boivin G.
    Vaccine; 2014 Sep 29; 32(43):5730-9. PubMed ID: 25173481
    [Abstract] [Full Text] [Related]

  • 20. N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model.
    Amidi M, Romeijn SG, Verhoef JC, Junginger HE, Bungener L, Huckriede A, Crommelin DJ, Jiskoot W.
    Vaccine; 2007 Jan 02; 25(1):144-53. PubMed ID: 16973248
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.